Which has stronger valuation & earnings, KLRA or AURA?

Aura Biosciences is trading at a lower price-to-earnings ratio than Kailera Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Kailera Therapeutics N/A N/A N/A -$3.65 thousand N/A Aura Biosciences N/A N/A -$106.19M -$1.74 N/A

Is KLRA or AURA more profitable?

Kailera Therapeutics' return on equity of 0.00% beat Aura Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Kailera Therapeutics N/A N/A N/A Aura Biosciences N/A -78.12% -64.08%

Does the media refer more to KLRA or AURA?

In the previous week, Kailera Therapeutics had 4 more articles in the media than Aura Biosciences. MarketBeat recorded 7 mentions for Kailera Therapeutics and 3 mentions for Aura Biosciences. Aura Biosciences' average media sentiment score of 0.83 beat Kailera Therapeutics' score of 0.43 indicating that Aura Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kailera Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Aura Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer MOR or AURA?

Aura Biosciences has a consensus target price of $20.50, suggesting a potential upside of 194.03%. Given Aura Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Aura Biosciences is more favorable than MorphoSys. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MorphoSys 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Aura Biosciences 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Is MOR or AURA more profitable?

Aura Biosciences has a net margin of 0.00% compared to MorphoSys' net margin of -226.79%. Aura Biosciences' return on equity of -78.12% beat MorphoSys' return on equity. Company Net Margins Return on Equity Return on Assets MorphoSys -226.79% -694.31% -22.55% Aura Biosciences N/A -78.12% -64.08%

Which has higher earnings and valuation, AURA or TRVI?

Trevi Therapeutics is trading at a lower price-to-earnings ratio than Aura Biosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aura Biosciences N/A N/A -$106.19M -$1.74 N/A Trevi Therapeutics N/A N/A -$42.76M -$0.32 N/A

Is AURA or TRVI more profitable?

Trevi Therapeutics' return on equity of -24.53% beat Aura Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Aura Biosciences N/A -78.12% -64.08% Trevi Therapeutics N/A -24.53% -23.37%

Does the media refer more to AURA or TRVI?

In the previous week, Aura Biosciences and Aura Biosciences both had 3 articles in the media. Trevi Therapeutics' average media sentiment score of 1.35 beat Aura Biosciences' score of 0.83 indicating that Trevi Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aura Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Trevi Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is AURA or IMNM more profitable?

Immunome's return on equity of -51.15% beat Aura Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Aura Biosciences N/A -78.12% -64.08% Immunome N/A -51.15% -47.32%

Does the media refer more to AURA or IMNM?

In the previous week, Immunome had 12 more articles in the media than Aura Biosciences. MarketBeat recorded 15 mentions for Immunome and 3 mentions for Aura Biosciences. Aura Biosciences' average media sentiment score of 0.83 beat Immunome's score of 0.36 indicating that Aura Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aura Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Immunome 4 Very Positive mention(s) 4 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable earnings and valuation, AURA or SLS?

SELLAS Life Sciences Group is trading at a lower price-to-earnings ratio than Aura Biosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aura Biosciences N/A N/A -$106.19M -$1.74 N/A SELLAS Life Sciences Group N/A N/A -$26.86M -$0.23 N/A

Is AURA or SLS more profitable?

SELLAS Life Sciences Group's return on equity of -47.12% beat Aura Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Aura Biosciences N/A -78.12% -64.08% SELLAS Life Sciences Group N/A -47.12% -42.63%

Does the media favor AURA or SLS?

In the previous week, SELLAS Life Sciences Group had 3 more articles in the media than Aura Biosciences. MarketBeat recorded 6 mentions for SELLAS Life Sciences Group and 3 mentions for Aura Biosciences. Aura Biosciences' average media sentiment score of 0.83 beat SELLAS Life Sciences Group's score of 0.49 indicating that Aura Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aura Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SELLAS Life Sciences Group 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Aura Biosciences (AURA) Competitors

$6.97 -0.03 (-0.40%)

As of 10:00 AM Eastern

Compare

AURA vs. KLRA, MOR, TRVI, IMNM, and SLS

Should you buy Aura Biosciences stock or one of its competitors? MarketBeat compares Aura Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Aura Biosciences include Kailera Therapeutics (KLRA), MorphoSys (MOR), Trevi Therapeutics (TRVI), Immunome (IMNM), and SELLAS Life Sciences Group (SLS). These companies are all part of the "pharmaceutical products" industry.

How does Aura Biosciences compare to Kailera Therapeutics?

Kailera Therapeutics (NASDAQ:KLRA) and Aura Biosciences (NASDAQ:AURA) are both pharmaceutical products companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, profitability, institutional ownership, earnings, valuation, media sentiment, dividends and analyst recommendations.

Kailera Therapeutics currently has a consensus target price of $42.75, suggesting a potential upside of 114.29%. Aura Biosciences has a consensus target price of $20.50, suggesting a potential upside of 194.03%. Given Aura Biosciences' higher possible upside, analysts clearly believe Aura Biosciences is more favorable than Kailera Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kailera Therapeutics	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	3.00
Aura Biosciences	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Kailera Therapeutics' return on equity of 0.00% beat Aura Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kailera Therapeutics	N/A	N/A	N/A
Aura Biosciences	N/A	-78.12%	-64.08%

Aura Biosciences is trading at a lower price-to-earnings ratio than Kailera Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kailera Therapeutics	N/A	N/A	N/A	-$3.65 thousand	N/A
Aura Biosciences	N/A	N/A	-$106.19M	-$1.74	N/A

In the previous week, Kailera Therapeutics had 4 more articles in the media than Aura Biosciences. MarketBeat recorded 7 mentions for Kailera Therapeutics and 3 mentions for Aura Biosciences. Aura Biosciences' average media sentiment score of 0.83 beat Kailera Therapeutics' score of 0.43 indicating that Aura Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kailera Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Aura Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

96.8% of Aura Biosciences shares are owned by institutional investors. 1.9% of Aura Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Kailera Therapeutics beats Aura Biosciences on 7 of the 12 factors compared between the two stocks.

How does Aura Biosciences compare to MorphoSys?

MorphoSys (NASDAQ:MOR) and Aura Biosciences (NASDAQ:AURA) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, earnings, analyst recommendations, media sentiment and profitability.

Aura Biosciences has lower revenue, but higher earnings than MorphoSys. MorphoSys is trading at a lower price-to-earnings ratio than Aura Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MorphoSys	$238.28M	11.99	-$205.35M	-$3.48	N/A
Aura Biosciences	N/A	N/A	-$106.19M	-$1.74	N/A

Aura Biosciences has a net margin of 0.00% compared to MorphoSys' net margin of -226.79%. Aura Biosciences' return on equity of -78.12% beat MorphoSys' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MorphoSys	-226.79%	-694.31%	-22.55%
Aura Biosciences	N/A	-78.12%	-64.08%

MorphoSys has a beta of 1.2, suggesting that its share price is 20% more volatile than the broader market. Comparatively, Aura Biosciences has a beta of 0.4, suggesting that its share price is 60% less volatile than the broader market.

In the previous week, Aura Biosciences had 3 more articles in the media than MorphoSys. MarketBeat recorded 3 mentions for Aura Biosciences and 0 mentions for MorphoSys. Aura Biosciences' average media sentiment score of 0.83 beat MorphoSys' score of 0.00 indicating that Aura Biosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
MorphoSys	Neutral
Aura Biosciences	Positive

Aura Biosciences has a consensus target price of $20.50, suggesting a potential upside of 194.03%. Given Aura Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Aura Biosciences is more favorable than MorphoSys.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MorphoSys	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Aura Biosciences	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

18.4% of MorphoSys shares are held by institutional investors. Comparatively, 96.8% of Aura Biosciences shares are held by institutional investors. 0.1% of MorphoSys shares are held by company insiders. Comparatively, 1.9% of Aura Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Aura Biosciences beats MorphoSys on 12 of the 15 factors compared between the two stocks.

How does Aura Biosciences compare to Trevi Therapeutics?

Aura Biosciences (NASDAQ:AURA) and Trevi Therapeutics (NASDAQ:TRVI) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, dividends, risk, earnings, valuation and media sentiment.

96.8% of Aura Biosciences shares are held by institutional investors. Comparatively, 95.8% of Trevi Therapeutics shares are held by institutional investors. 1.9% of Aura Biosciences shares are held by insiders. Comparatively, 18.3% of Trevi Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Trevi Therapeutics' return on equity of -24.53% beat Aura Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aura Biosciences	N/A	-78.12%	-64.08%
Trevi Therapeutics	N/A	-24.53%	-23.37%

In the previous week, Aura Biosciences and Aura Biosciences both had 3 articles in the media. Trevi Therapeutics' average media sentiment score of 1.35 beat Aura Biosciences' score of 0.83 indicating that Trevi Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aura Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Trevi Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Aura Biosciences has a beta of 0.4, meaning that its share price is 60% less volatile than the broader market. Comparatively, Trevi Therapeutics has a beta of 1, meaning that its share price has a similar volatility profile to the broader market.

Aura Biosciences currently has a consensus target price of $20.50, indicating a potential upside of 194.03%. Trevi Therapeutics has a consensus target price of $22.67, indicating a potential upside of 37.22%. Given Aura Biosciences' higher probable upside, research analysts clearly believe Aura Biosciences is more favorable than Trevi Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aura Biosciences	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Trevi Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.00

Trevi Therapeutics is trading at a lower price-to-earnings ratio than Aura Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aura Biosciences	N/A	N/A	-$106.19M	-$1.74	N/A
Trevi Therapeutics	N/A	N/A	-$42.76M	-$0.32	N/A

Summary

Trevi Therapeutics beats Aura Biosciences on 10 of the 13 factors compared between the two stocks.

How does Aura Biosciences compare to Immunome?

Aura Biosciences (NASDAQ:AURA) and Immunome (NASDAQ:IMNM) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, earnings, valuation, media sentiment, profitability, analyst recommendations and risk.

Aura Biosciences has a beta of 0.4, indicating that its stock price is 60% less volatile than the broader market. Comparatively, Immunome has a beta of 2.07, indicating that its stock price is 107% more volatile than the broader market.

Immunome's return on equity of -51.15% beat Aura Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aura Biosciences	N/A	-78.12%	-64.08%
Immunome	N/A	-51.15%	-47.32%

Aura Biosciences currently has a consensus target price of $20.50, indicating a potential upside of 194.03%. Immunome has a consensus target price of $33.17, indicating a potential upside of 46.48%. Given Aura Biosciences' higher possible upside, research analysts plainly believe Aura Biosciences is more favorable than Immunome.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aura Biosciences	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Immunome	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.86

Aura Biosciences has higher earnings, but lower revenue than Immunome. Immunome is trading at a lower price-to-earnings ratio than Aura Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aura Biosciences	N/A	N/A	-$106.19M	-$1.74	N/A
Immunome	$6.94M	369.50	-$212.39M	-$2.38	N/A

96.8% of Aura Biosciences shares are held by institutional investors. Comparatively, 44.6% of Immunome shares are held by institutional investors. 1.9% of Aura Biosciences shares are held by insiders. Comparatively, 7.2% of Immunome shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Immunome had 12 more articles in the media than Aura Biosciences. MarketBeat recorded 15 mentions for Immunome and 3 mentions for Aura Biosciences. Aura Biosciences' average media sentiment score of 0.83 beat Immunome's score of 0.36 indicating that Aura Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aura Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Immunome	4 Very Positive mention(s)	4 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Immunome beats Aura Biosciences on 8 of the 14 factors compared between the two stocks.

How does Aura Biosciences compare to SELLAS Life Sciences Group?

Aura Biosciences (NASDAQ:AURA) and SELLAS Life Sciences Group (NASDAQ:SLS) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, risk, profitability, dividends, valuation, institutional ownership and earnings.

SELLAS Life Sciences Group's return on equity of -47.12% beat Aura Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aura Biosciences	N/A	-78.12%	-64.08%
SELLAS Life Sciences Group	N/A	-47.12%	-42.63%

SELLAS Life Sciences Group is trading at a lower price-to-earnings ratio than Aura Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aura Biosciences	N/A	N/A	-$106.19M	-$1.74	N/A
SELLAS Life Sciences Group	N/A	N/A	-$26.86M	-$0.23	N/A

Aura Biosciences has a beta of 0.4, indicating that its stock price is 60% less volatile than the broader market. Comparatively, SELLAS Life Sciences Group has a beta of 2.42, indicating that its stock price is 142% more volatile than the broader market.

Aura Biosciences presently has a consensus target price of $20.50, suggesting a potential upside of 194.03%. SELLAS Life Sciences Group has a consensus target price of $10.00, suggesting a potential downside of 21.29%. Given Aura Biosciences' higher possible upside, equities research analysts plainly believe Aura Biosciences is more favorable than SELLAS Life Sciences Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aura Biosciences	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
SELLAS Life Sciences Group	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

96.8% of Aura Biosciences shares are owned by institutional investors. Comparatively, 17.4% of SELLAS Life Sciences Group shares are owned by institutional investors. 1.9% of Aura Biosciences shares are owned by insiders. Comparatively, 1.3% of SELLAS Life Sciences Group shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, SELLAS Life Sciences Group had 3 more articles in the media than Aura Biosciences. MarketBeat recorded 6 mentions for SELLAS Life Sciences Group and 3 mentions for Aura Biosciences. Aura Biosciences' average media sentiment score of 0.83 beat SELLAS Life Sciences Group's score of 0.49 indicating that Aura Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aura Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
SELLAS Life Sciences Group	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

SELLAS Life Sciences Group beats Aura Biosciences on 7 of the 12 factors compared between the two stocks.

Get Aura Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AURA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AURA vs. The Competition

Export

Metric	Aura Biosciences	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$721.15M	$3.71B	$7.05B	$12.61B
Dividend Yield	N/A	2.20%	2.68%	8.00%
P/E Ratio	-4.01	20.85	27.10	24.26
Price / Sales	N/A	314.01	588.85	117.88
Price / Cash	N/A	61.98	29.22	49.36
Price / Book	3.23	8.49	10.85	6.29
Net Income	-$106.19M	$23.83M	$3.58B	$330.66M
7 Day Performance	-0.83%	-3.56%	-2.12%	-1.35%
1 Month Performance	8.77%	6.31%	3.27%	-0.64%
1 Year Performance	3.29%	48.30%	26.33%	19.08%

Aura Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AURA Aura Biosciences	2.1887 of 5 stars	$6.98 -0.4%	$20.50 +193.9%	+9.4%	$718.56M	N/A	N/A	50	Analyst Downgrade
KLRA Kailera Therapeutics	4.1789 of 5 stars	$22.24 -4.5%	$42.75 +92.2%	N/A	$2.88B	N/A	N/A	145	Short Interest Increase
MOR MorphoSys	N/A	$18.96 flat	N/A	N/A	$2.86B	$238.28M	N/A	730
TRVI Trevi Therapeutics	3.482 of 5 stars	$19.50 +8.6%	$22.67 +16.2%	+152.2%	$2.77B	N/A	N/A	20	News Coverage Positive News High Trading Volume
IMNM Immunome	3.2976 of 5 stars	$24.39 +2.1%	$33.17 +36.0%	+163.9%	$2.76B	$6.94M	N/A	40

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AURA) was last updated on 7/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Aura Biosciences (AURA) Competitors

AURA vs. KLRA, MOR, TRVI, IMNM, and SLS

How does Aura Biosciences compare to Kailera Therapeutics?

Summary

How does Aura Biosciences compare to MorphoSys?

Summary

How does Aura Biosciences compare to Trevi Therapeutics?

Summary

How does Aura Biosciences compare to Immunome?

Summary

How does Aura Biosciences compare to SELLAS Life Sciences Group?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AURA vs. The Competition

Aura Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Aura Biosciences (AURA) Competitors

AURA vs. KLRA, MOR, TRVI, IMNM, and SLS

How does Aura Biosciences compare to Kailera Therapeutics?

Do analysts prefer KLRA or AURA?

Is KLRA or AURA more profitable?

Which has stronger valuation & earnings, KLRA or AURA?

Does the media refer more to KLRA or AURA?

Do insiders and institutionals hold more shares of KLRA or AURA?

Summary

How does Aura Biosciences compare to MorphoSys?

Which has higher earnings & valuation, MOR or AURA?

Is MOR or AURA more profitable?

Which has more volatility and risk, MOR or AURA?

Does the media favor MOR or AURA?

Do analysts prefer MOR or AURA?

Do institutionals & insiders hold more shares of MOR or AURA?

Summary

How does Aura Biosciences compare to Trevi Therapeutics?

Do institutionals & insiders have more ownership in AURA or TRVI?

Is AURA or TRVI more profitable?

Does the media refer more to AURA or TRVI?

Which has more risk and volatility, AURA or TRVI?

Do analysts rate AURA or TRVI?

Which has higher earnings and valuation, AURA or TRVI?

Summary

How does Aura Biosciences compare to Immunome?

Which has more risk & volatility, AURA or IMNM?

Is AURA or IMNM more profitable?

Do analysts rate AURA or IMNM?

Which has higher valuation & earnings, AURA or IMNM?

Do insiders and institutionals believe in AURA or IMNM?

Does the media refer more to AURA or IMNM?

Summary

How does Aura Biosciences compare to SELLAS Life Sciences Group?

Is AURA or SLS more profitable?

Which has preferable earnings and valuation, AURA or SLS?

Which has more volatility & risk, AURA or SLS?

Do analysts rate AURA or SLS?

Do institutionals and insiders hold more shares of AURA or SLS?

Does the media favor AURA or SLS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AURA vs. The Competition

Aura Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools